Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era
With the markedly increased cure rate for children with newly diagnosed pediatric B-cell acute lymphoblastic leukemia (B-ALL), relapse and refractory B-ALL (R/R B-ALL) remain the primary cause of death worldwide due to the limitations of multidrug chemotherapy. As we now have a more profound underst...
Saved in:
Main Authors: | Shang Mengxuan (Author), Zhou Fen (Author), Jin Runming (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
by: Jiao Xie, et al.
Published: (2023) -
Dual intra- and extracranial lymphoblastic chloromas in relapsed Pediatric Acute Lymphoblastic Leukemia
by: Kainaat Javed, et al.
Published: (2022) -
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
by: Vairy S, et al.
Published: (2018) -
Precision Medicine for Acute Lymphoblastic Leukemia in Children: A Review
by: Anish Ray, et al.
Published: (2024) -
Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia
by: Suliman A. Alsagaby
Published: (2019)